Reliability, validity of the Vitiligo Extent Score | CCID
Measurement of Therapeutic Response Using the Vitiligo Area Scoring Index in People With Vitiligo: - YouTube
Ruxolitinib 1.5% to be approved late 2021 to early 2022. Very promising results, especially on the face : r/Vitiligo
Vitiligo Area Scoring Index (VASI) of total skin and area specific, and... | Download Table
Vitiligo - Roshan Homeo Clinic
Effect of Vitiligo Area Scoring Index on the quality of life in patients with vitiligo Hammam MA, Yasien HA, Algharably AF - Menoufia Med J
Oral Ritlecitinib For Active Non-Segmental Vitiligo Treatment - MDNewsline
Interview guide excerpt: F-VASI meaningful change illustrative graphic... | Download Scientific Diagram
Disease severity indexes and treatment evaluation criteria in vitiligo - Document - Gale OneFile: Health and Medicine
The mean Vitiligo Area Scoring Index (VASI) score with standard error... | Download Scientific Diagram
Patients with nonsegmental vitiligo see significant repigmentation with povorcitinib
Deux essais randomisés montrent les effets du Ruxolitinib 1,5% crème dans le vitiligo | APHP
Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI) | Dermatology and Therapy
Figure 1 from Vitiligo Extent Tensity Index (VETI) score: a new definition, assessment and treatment evaluation criteria in vitiligo | Semantic Scholar
Vitiligo Bordeaux : la recherche
NEJM on X: "In two phase 3, double-blind, placebo-controlled trials, the Janus kinase inhibitor ruxolitinib showed superiority to vehicle control in facial repigmentation of vitiligo. https://t.co/zgkUMYHtIO https://t.co/gP3cgVCrtK" / X
Boston research offers new treatment hope for vitiligo
Vitiligo VASI Score for Vitiligo (Treatment Assessment) - YouTube
AbbVie Announces Upadacitinib Meets Primary Endpoint of Phase 2 Trial for Vitiligo - Advances to Phase 3 - LiVDerm
Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative - ScienceDirect
BAD 2022 - Phase 2 Vitiligo Study (156-week data)
